Cutler Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-17,900
| Closed | -$155K | – | 3811 |
|
|
2022
Q4 | $155K | Sell |
17,900
-19,400
| -52% | -$5.48M | 0.01% | 920 |
|
|
2022
Q3 | $540K | Buy |
37,300
+200
| +0.5% | +$42.5K | 0.04% | 495 |
|
|
2022
Q2 | $61K | Sell |
37,100
-8,200
| -18% | -$1.68M | ﹤0.01% | 1799 |
|
|
2022
Q1 | $124K | Buy |
45,300
+36,500
| +415% | +$7.94M | 0.01% | 1539 |
|
|
2021
Q4 | $11K | Buy |
+8,800
| New | +$2.26M | ﹤0.01% | 3599 |
|
|
2021
Q3 | – | Sell |
-5,000
| Closed | -$9K | – | 5708 |
|
|
2021
Q2 | $9K | Sell |
5,000
-5,900
| -54% | -$1.79M | ﹤0.01% | 3962 |
|
|
2021
Q1 | $121K | Buy |
10,900
+6,300
| +137% | +$1.7M | 0.01% | 1624 |
|
|
2020
Q4 | $27K | Buy |
+4,600
| New | +$1.19M | ﹤0.01% | 2447 |
|
|
2020
Q3 | – | Sell |
-4,000
| Closed | -$36K | – | 4668 |
|
|
2020
Q2 | $36K | Hold |
4,000
| – | – | ﹤0.01% | 1969 |
|
|
2020
Q1 | $109K | Sell |
4,000
-10,000
| -71% | -$3.03M | 0.01% | 1289 |
|
|
2019
Q4 | $188K | Buy |
14,000
+9,600
| +218% | +$2.66M | 0.01% | 850 |
|
|
2019
Q3 | $37K | Sell |
4,400
-4,100
| -48% | -$955K | ﹤0.01% | 1746 |
|
|
2019
Q2 | $16K | Sell |
8,500
-18,200
| -68% | -$4.2M | ﹤0.01% | 2357 |
|
|
2019
Q1 | $83K | Buy |
26,700
+11,900
| +80% | +$3.75M | 0.01% | 1106 |
|
|
2018
Q4 | $189K | Buy |
14,800
+1,600
| +12% | +$511K | 0.02% | 665 |
|
|
2018
Q3 | $520K | Sell |
13,200
-3,300
| -20% | -$1.14M | 0.04% | 450 |
|
|
2018
Q2 | $586K | Sell |
16,500
-400
| -2% | -$112K | 0.05% | 388 |
|
|
2018
Q1 | $955K | Sell |
16,900
-21,900
| -56% | -$6.8M | 0.08% | 235 |
|
|
2017
Q4 | $1.82M | Sell |
38,800
-19,500
| -33% | -$6.26M | 0.07% | 191 |
|
|
2017
Q3 | $2.09M | Sell |
58,300
-35,100
| -38% | -$10.4M | 0.08% | 187 |
|
|
2017
Q2 | $1.77M | Buy |
93,400
+10,500
| +13% | +$2.78M | 0.07% | 247 |
|
|
2017
Q1 | $347K | Buy |
82,900
+7,500
| +10% | +$2.12M | 0.01% | 836 |
|
|
2016
Q4 | $400K | Sell |
75,400
-5,800
| -7% | -$1.72M | 0.01% | 822 |
|
|
2016
Q3 | $1.18M | Buy |
81,200
+47,000
| +137% | +$13.9M | 0.05% | 272 |
|
|
2016
Q2 | $142K | Buy |
34,200
+24,700
| +260% | +$6.51M | 0.01% | 1382 |
|
|
2016
Q1 | $162K | Sell |
9,500
-9,600
| -50% | -$2.54M | 0.01% | 1166 |
|
|
2015
Q4 | $631K | Buy |
+19,100
| New | +$5.49M | 0.04% | 517 |
|
Other funds holding BIIB
Cutler Group's BIIB Position: Q3 2023 in Review
Cutler Group sold out of Biogen (BIIB) in Q3 2023, closing a stake of 1,106 shares — an estimated $315K sold.
Cutler Group first reported a position in BIIB in Q4 2015 and held it in 29 quarters. The position peaked at $33.3M in Q2 2017. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.
- Cutler Group reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,106 Biogen shares in Q3 2023, an estimated $315K.
- Cutler Group first reported a position in Biogen in Q4 2015 and held it in 29 quarters.
- Cutler Group's Biogen position peaked at $33.3M in Q2 2017.
- 965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.